FDA Questions Pfizer ' s Chantix Trial Data

The FDA says Pfizer ' s study of neuropsychiatric effects of its smoking cessation drug Chantix may have presented confusing data on adverse events, potentially biasing the research.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news